The Patient’s Point of View: COVID-19 and Neuroendocrine Tumor Disease
The assessment of cancer patient care during the COVID-19 pandemic has been mainly reported from a physician’s perspective. Patients with rare tumor entities such as neuroendocrine tumors (NET), which require a complex and specialized care infrastructure, were highly affected by the COVID-19 crisis....
Main Authors: | Sebastian Krug, Maryam Khosravian, Julia Weissbach, Katharina George, Marko Damm, Jakob Garbe, Jens Walldorf, Philipp A. Reuken, Tania Amin, Alexander Siebenhüner, Jonas Rosendahl, Thomas M. Gress, Patrick Michl, Jörg Schrader, Anja Rinke |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/3/613 |
Similar Items
-
Finding the Appropriate Therapeutic Strategy in Patients with Neuroendocrine Tumors of the Pancreas: Guideline Recommendations Meet the Clinical Reality
by: Sebastian Krug, et al.
Published: (2021-07-01) -
CUX1—Transcriptional Master Regulator of Tumor Progression in Pancreatic Neuroendocrine Tumors
by: Sebastian Krug, et al.
Published: (2020-07-01) -
Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
by: Thomas Gress, et al.
Published: (2012-02-01) -
Leptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms
by: Leonidas Apostolidis, et al.
Published: (2021-03-01) -
Targeting HDACs in Pancreatic Neuroendocrine Tumor Models
by: Rosa Lynn Schmitz, et al.
Published: (2021-06-01)